Free Trial
NASDAQ:NRSN

NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

NeuroSense Therapeutics logo
$1.36 +0.08 (+6.25%)
(As of 12/20/2024 05:40 PM ET)

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

Key Stats

Today's Range
$1.22
$1.42
50-Day Range
$0.85
$1.36
52-Week Range
$0.51
$2.33
Volume
1.27 million shs
Average Volume
274,128 shs
Market Capitalization
$18.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
10th Percentile Overall Score

NRSN MarketRank™: 

NeuroSense Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 904th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroSense Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroSense Therapeutics is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    2.10% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently increased by 25.69%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NeuroSense Therapeutics does not currently pay a dividend.

  • Dividend Growth

    NeuroSense Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.10% of the float of NeuroSense Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroSense Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroSense Therapeutics has recently increased by 25.69%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NeuroSense Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for NRSN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.04% of the stock of NeuroSense Therapeutics is held by institutions.

  • Read more about NeuroSense Therapeutics' insider trading history.
Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRSN Stock News Headlines

NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position
Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
NeuroSense Therapeutics Regains Nasdaq Compliance
NeuroSense cut to Hold at Maxim following PrimeC FDA feedback
See More Headlines

NRSN Stock Analysis - Frequently Asked Questions

NeuroSense Therapeutics' stock was trading at $0.7850 at the start of the year. Since then, NRSN stock has increased by 73.2% and is now trading at $1.36.
View the best growth stocks for 2024 here
.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) released its quarterly earnings results on Wednesday, December, 18th. The company reported ($0.11) earnings per share for the quarter.

NeuroSense Therapeutics (NRSN) raised $13 million in an IPO on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

Top institutional investors of NeuroSense Therapeutics include XTX Topco Ltd (0.34%).

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE).

Company Calendar

Last Earnings
12/18/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRSN
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Net Income
$-11,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.14) per share

Miscellaneous

Free Float
9,922,000
Market Cap
$18.59 million
Optionable
Not Optionable
Beta
1.38
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:NRSN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners